CytomX Therapeutics (CTMX) showcased promising results for its Varseta-M drug in treating late-stage metastatic colorectal cancer, despite some toxicity concerns. Following encouraging Q1 2026 data, CTMX raised $234.2 million, extending its cash runway to at least the second half of 2028 and enabling expanded development of Varseta-M. The company plans to report updated monotherapy data in the second half of 2026 and may start a registrational trial in the first half of 2027. This funding and progress highlight Varseta-M's potential in multiple cancer indications beyond colorectal cancer.
The US government, under the Trump administration, is negotiating to take equity stakes in domestic drone manufacturers to accelerate production, reduce costs, and lessen dependence on Chinese drone components. This move supports the 'Drone Dominance...
Bank of N.T. Butterfield announced it will acquire CIBC's 91.7% stake in CIBC Caribbean Bank Limited for approximately $1.8 billion, combining cash and shares. This acquisition aims to create a larger banking and wealth management platform in the Car...
Peec AI, an AI search analytics platform, surpassed $10 million in annual recurring revenue just 16 months after launch, doubling revenue in the last five months. The company is expanding rapidly, opening its first US office in New York to meet growi...
The National Crime Prevention Council (NCPC) has called on lawmakers to reject the House's Kids Internet and Digital Safety Act (H.R. 7757), criticizing it as insufficient for protecting children online. NCPC argues the bill weakens state powers and ...
Fannie Mae has started marketing a sale of approximately 2,333 reperforming loans with an unpaid principal balance of about $565 million. These loans were previously delinquent but have since become current. Buyers must offer loss mitigation options,...
